title: Tumour lysis syndrome with acute renal failure during imatinib therapy.
authors.forename: Ridvan
authors.initials: R
authors.lastname: Ali
authors.forename: Fahir
authors.initials: F
authors.lastname: Ozkalemkas
authors.forename: Atilla
authors.initials: A
authors.lastname: Ozkan
authors.forename: Tulay
authors.initials: T
authors.lastname: Ozcelik
authors.forename: Vildan
authors.initials: V
authors.lastname: Ozkocaman
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Akdag
authors.forename: Ulku
authors.initials: U
authors.lastname: Ozan
authors.forename: Ahmet
authors.initials: A
authors.lastname: Tunali
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D007680:Kidney Neoplasms / Q000139:chemically induced* / Q000188:drug therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects*; D015275:Tumor Lysis Syndrome / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases